Non-nucleoside reverse transcriptase inhibitors: The NNRTI boom

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 6, 1999, Pages 285-314

  Pedersen, Ole S ^a   Pedersen, Erik B ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Delavirdine; Efavirenz; HEPT; HIV 1; Nevirapine; Non nucleoside reverse transcriptase inhibitors; Trovirdine

Indexed keywords

DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TROVIRDINE;

DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW;

EID: 0032737069     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000601     Document Type: Review

References (105)

1. Ahgren C, Backro K, Bell FW, Cantrell AS, Clemens M, Colacino JM, Deeter JB, Engelhardt JA, Hogberg M, Jaskunas SR, Johansson NG, Jordan CL, Kasher JS, Kinnick MD, Lind P, Lopez C, Morin JM Jr, Muesing MA, Noreen R, Oberg B, Paget CJ, Palkowitz JA, Parrish CA, Pranc P, Rippy MK, Rydergard C, Sahlberg C, Swanson S, Ternansky RJ, Unge T, Vasileff RT, Vrang L, West SJ, Zhang H & Zhou X-X (1995) The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 39:1329-1335.
2. Althaus IW, Gonzales AJ, Chou JJ, Romero DL, Deibel MR, Chou KC, Kezdy FJ, Resnick L, Busso ME & So AG (1993) The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase. Journal of Biological Chemistry 268:14875-14880.
3. Althaus IW, Chou K-C, Lemay RJ, Franks KM, Deibel MR, Kezdy FJ, Resnick L, Busso ME, So AG, Downey KM, Romero DL, Thomas RC, Aristoff PA, Tarpley WG & Reusser F (1996) The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase. Biochemical Pharmacology 51:743-750.
4. Arranz E, Díaz JA, Ingate ST, Witrouw M, Pannecouque C, Balzarini J, De Clercq E & Vega S (1998) Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication. Journal of Medicinal Chemistry 41:4109-4117.
5. Artico M (1996) Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials. Il Farmaco 51:305-331.
6. Artico M, Massa S, Mai A, Marongiu ME, Piras G, Tramontino E & La Colla P (1993) 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus Type 1. Antiviral Chemistry & Chemotherapy 4:361-368.
7. Artico M, Silvestri R, Pagnozzi E, Stefancich G, Massa S, Loi AG, Putzolu M, Corrias S, Spiga MG & La Colla P (1996) 5-H-Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): a novel class of non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry Letters 4:837-850.
8. Baba M, Yuasa S, Niwa T, Yamamoto M, Yabuuchi S, Takashima H, Ubasawa M, Tanaka H, Miyasaka T, Walker RT, Balzarini J, De Clercq E & Shigeta S (1993). Effect of human serum on the in vitro anti-HIV-1 activity of 1-[(2Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding. Biochemical Pharmacology 45:2507-2512.
9. Bader JP, McMahon JB, Schultz RJ, Narayanan VL, Pierce JB, Harrison WA, Weislow OS, Midelfort CF, Stinson SF & Boyd MR (1991) Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proceedings of the National Academy of Sciences, USA 88:6740-6744.
10. Balzarini J, Brouwer WG, Felauer EE, De Clercq E & Karlsson A (1995) Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Research 27:219-236.
11. Barnard J, Borkow G & Parniak MA (1997) The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 36:7786-7792.
12. Barth B, Dierich M, Heinisch G, Jenny V, Matuszczak B, Mereiter K, Planer R, Schöpf I, Stoiber H, Traugott T & Aufschnaiter PV (1996) Pyridazino[3,4-b][1,5]benzoxazepin-5(6H)-ones: synthesis and biological evaluation. Antiviral Chemistry & Chemotherapy 7:300-312.
13. Bell FW, Cantrell AS, Högberg M, Jaskunas SR, Johansson NG, Jordan CL, Kinnick MD, Lind P, Morin JM Jr, Noréen R, Öberg B, Palkowitz JA, Parrish CA, Pranc P, Sahlberg C, Ternansky RJ, Vasileff RT, Vrang L, West SJ, Zhang H & Zhou X-X (1995) Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship of PETT analogs. Journal of Medicinal Chemistry 38:4929-4936.
14. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA & Parniak MA (1997) Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor for HIV-1 reverse transcriptase. Journal of Virology 71:3023-3030.
15. Botta M, Artico M, Massa S, Gambacorta A, Marongiu ME, Pani A & La Colla P (1992) Synthesis, antimicrobial and antiviral activities of isotrimethoprim and some related derivatives. European Journal of Medicinal Chemistry 27:251-257.
16. Breslin HJ, Kukla MJ, Ludovici DW, Mohrbacher R, Ho W, Miranda M, Rodgers JD, Hitchens TK, Leo G, Gauthier DA, Ho CY, Scott MK, De Clercq E, Pauwels R, Andries K, Janssen MAC & Janssen PAJ (1995) Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 3. Journal of Medicinal Chemistry 38:771-793.
17. Buckheit RW Jr, Fliakas-Boltz, V, Russell JD, Snow M, Pallansch LA, Yang SS, Bader JP, Khan TN & Zanger M (1996) A diaryl-sulphone non-nucleoside reverse transcriptase inhibitor with a unique sensitivity profile to drug resistant virus isolates. Antiviral Chemistry & Chemotherapy 7:243-252.
18. Buckheit RW Jr, Snow MJ, Fliakas-Boltz V, Kinjerski TL, Russell JD, Pallansch LA, Brouwer WG & Yang SS (1997) Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrobial Agents and Chemotherapy 41:831-837.
19. Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Greco G, Novellino E, Altamura S & Di Renzo L (1996) Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity. Journal of Medicinal Chemistry 39:2672-2680.
20. Cantrell AS, Engelhardt P, Högberg M, Jaskunas SR, Johansson NG, Jordan CL, Kangasmetsä J, Kinnick MD, Lind P, Morin JM Jr, Muesing MA, Noreén R, Öberg B, Pranc P, Sahlberg C, Ternansky RJ, Vasileff RT, Vrang L, West SJ & Zhang H (1996) Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. Journal of Medicinal Chemistry 39: 4261-4274.
21. Chimirri A, Grasso S, Molica C, Monforte A-M, Monforte P, Zappala M, Bruno G, Nicolo F, Witvrouw M, Jonckeere H, Balzarini J & De Clercq E (1997) Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2′,6′-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chemistry & Chemotherapy 8:363-370.
22. Cushman M, Golebiewski M, Buckheit RW Jr, Graham L & Rice WG (1995) Synthesis and biological evaluation of an alkenyldiarylmethane (ADAM) which acts as a novel non-nucleoside HIV-1 recerse transcriptase inhibitor. Bioorganic & Medicinal Chemistry Letters 5:2713-2716.
23. Cushman M, Golebiewski WM, Graham L, Turpin JA, Rice WG, Fliakas-Boltz V & Buckheit RW Jr (1996) Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors. Journal of Medicinal Chemistry 39:3217-3227.
24. Cushman M, Casimiro-Garcia A, Hejchman E, Ruell JA, Huang M, Schaeffer CA, Williamson K, Rice WG & Buckheit RW Jr (1998a) New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors. Journal of Medicinal Chemistry 41:2076-2089.
25. Cushman M, Casimiro-Garcia A, Williamson K & Rice WG (1998b) Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index. Bioorganic and Medicinal Chemistry Letters 8:195-198.
26. Cywin CL, Klunder JM, Hoermann M, Brickwood JR, David E, Grob PM, Schwartz R, Pauletti D, Barringer KJ, Shih C-K, Sorge CL, Erickson DA, Joseph DP & Hattox SE (1998) Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones. Journal of Medicinal Chemistry 41:2972-2984.
27. Danel K, Larsen E, Pedersen EB, Vestergaard BF & Nielsen C (1996) Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. Journal of Medicinal Chemistry 39:2427-2431.
28. Danel K, Nielsen C & Pedersen EB (1997) Anti-HIV active naphtyl analogues of HEPT and DABO. Acta Chemica Scandinavica 51:426-430.
29. Danel K, Pedersen EB & Nielsen C (1998) Synthesis and anti-HIV-1 activity of novel 2,3-dihydro-7H-thiazolo[3,2-a]pyrimidin-7-ones. Journal of Medicinal Chemistry 41:191-198.
30. De Clercq E (1998a) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Research 38:153-179.
31. De Clercq E (1998b) New perspectives for the treatment of HIV infections. Collection of Czechoslovak Chemical Communications 63:449-479.
32. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PAJ, Hughes SH & Arnold E (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Structural Biology 2:407-415.
33. Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey KM, Althaus IW, Reusser F, Busso M, Resnick L, Mayers DL, Lane J, Aristoff PA, Thomas RC & Tarpley WG (1993) U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrobial Agents and Chemotherapy 37:1127-1131.
34. Fujiwara T, Sato A, El-Farrash M, Miki S, Abe K, Isaka Y, Kodama M, Wu Y, Chen BL, Harada H, Sugimoto H, Hatanaka M & Hinuma Y (1998) S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 42:1340-1345.
35. Fuller RW, Bokesch HR, Gustafson KR, McKee TC, Cardellina JH II, McMahon JB, Cragg GM, Soearto DD & Boyd MR (1994) HIV-inhibitory coumarins from latex of the tropical rainforest tree Calophyllum teysmannii var. Inophylloide. Bioorganic & Medicinal Chemistry Letters 4:1961-1964.
36. Galinis DL, Fuller WT, McKee TC, Cardellina JH II, Gulakowski RJ, McMahon JB & Boyd MR (1996) Structure-activity modifications of the HIV-1 inhibitors (+)-calanolide A and (-)-calanolide B. Journal of Medicinal Chemistry 39:4507-4510.
37. Genin MJ, Poel TJ, Yagi Y, Biles C, Althaus I, Keiser BJ, Kopta LA, Friis JM, Reusser F, Adams WJ, Olmsted RA, Voorman RL, Thomas RC & Romero DL (1996) Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationship and increased metabolic stability of novel substituted pyridine analogs. Journal of Medicinal Chemistry 39:5267-5275.
38. Glynn SL & Yazdanian M (1998) In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. Journal of Pharmaceutical Sciences 87:306-310.
39. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS, Hupe DJ, Emini EA & Stern AM (1991) Pyridinone derivatives: specifiic human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proceedings of the National Academy of Sciences, USA 88:6863-6867.
40. Hanasaki Y, Watanabe H, Katsuura K, Takayama H, Shirakawa S, Yamaguchi K, Sakai S-I, Ijichi K, Fujiwara M, Konno K, Yokota T, Shigeta S & Baba M (1995) Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors. Journal of Medicinal Chemistry 38:2038-2040.
41. Hargrave KD, Proudfoot JR, Grozinger KG, Cullen E, Kapadia SR, Patel UR, Fuchs VU, Mauldin SC, Vitous J, Behnke ML, Klunder JM, Pal K, Skiles JW, McNeil DW, Rose JM, Chow GC, Skoog MT, Wu JC, Schmidt G, Engel WW, Eberlein WG, Saboe TD, Campbell SJ, Rosenthal AS & Adams J (1991) Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. Journal of Medicinal Chemistry 34:2231-2241.
42. Heinisch G, Huber E, Matuszczak B, Maurer A & Prillinger U (1997a) Synthesis of pyridazino[3,4-b][1,5]benzodiazepin-5-ones and their biological evaluation as non-nucleoside HIV reverse transcriptase inhibitors. Archive der Pharmacie 330:29-34.
43. Heinisch G, Matuszczak B, Pachler S & Rakowitz D (1997b) The inhibitory activity of diazinyl-substituted thiourea derivatives on human immunodeficiency virus type 1 reverse transcriptase. Antiviral Chemistry & Chemotherapy 8:443-446.
44. Hiroto H, Fujihashi T, Sakata T, Kaji A & Kaji H (1997) Tetrahydronaphtalenelignan compounds as potent anti-HIV type 1 agents. AIDS Research and Human Retroviruses 13:695-705.
45. Ho W, Kukla MJ, Breslin HJ, Ludovici DW, Grous PP, Diamond CJ, Miranda M, Rodgers JD, Ho CY, De Clercq E, Pauwels R, Andries K, Janssen MAC & Janssen PAJ (1995) Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 4. Journal of Medicinal Chemistry 38:794-802.
46. Hoffman JM, Wai JS, Thomas CM, Levin RB, Goldman ME & O'Brien JA (1992) Synthesis and evaluation of 2-pyridinone derivatives as specific HIV-1 reverse transcriptase inhibitors. 1. Phtalimidoalkyl and -alkylamino analogues. Journal of Medicinal Chemistry 35:3784-3791.
47. Hoffman JM, Smith AM, Rooney CS, Fisher TE, Wai JS, Thomas CM, Bamberger DL, Barnes JL, Williams TM, Jones JH, Olson BD, O'Brien JA, Goldman ME, Nunberg JH, Quintero JC, Schleif WA, Emini EA & Anderson PS (1993) Synthesis and evaluation of 2-pyridinone derivatives as specific reverse transcriptase inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and analogues. Journal of Medicinal Chemistry 36:953-966.
48. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK & Stuart DI (1996). Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes to the design of potent non-nucleoside inhibitors. Journal of Medicinal Chemistry 39:1589-1600.
49. Ijichi K, Fujiwara M, Nagano H, Matsumoto Y, Hanasaki Y, Ide T, Katsuura K, Takayama H, Shirakawa S, Aimi N, Shigeta S, Konno K, Matsushima M, Yokota T & Baba M (1996) Anti-HIV-1 activity of thiadiazole derivatives: structure-activity relationship, reverse transcriptase inhibition, and lipophilicity. Antiviral Research 31:87-94.
50. Kashman Y, Gustafson KR, Fuller RW, Cardellina II JH, McMahon JB, Currens MJ, Buckheit RW Jr, Hughes SH, Cragg GM & Boyd MR (1992) The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. Journal of Medicinal Chemistry 35:2735-2743.
51. Kelly TA, Proudfoot JR, McNeil DW, Patel UR, David E, Hargrave KD, Grob PM, Cardozo M, Agarwal A & Adams J (1995) Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs ot nevirapine. Journal of Medicinal Chemistry 38:4839-4847.
52. Kelly TA, McNeil DW, Rose JM, David E, Shih C-K & Grob PM (1997) Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones. Journal of Medicinal Chemistry 40:2430-2433.
53. Kim D-K, Kim Y-W, Gam J, Kim G, Lim J, Lee N, Kim H-T & Kim KH (1996) Synthesis and anti-HIV-1 activity of a series of 1-(alkoxymethyl)-5-alkyl-6-(arylselenyl)uracils and -2-thiouracils. Journal of Heterocyclic Chemistry 33:1275-1283.
54. Kleim J-P, Bender R, Billhardt U-M, Meichsner C, Riess G, Rîsner M, Winkler I & Paessens A (1993) Activity of a novel quinoxaline derivative against human imunnodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrobial Agents and Chemotherapy 37:1659-1664.
55. Kleim J-P, Bender R, Kirsch R, Meichsner C, Paessens A, Rösner M, Rübsamen-Waigmann H, Kaiser R, Wichers M, Schneweis KE, Winkler I & Reiss G (1995) Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrobial Agents and Chemotherapy 39:2253-2257.
56. Klunder JM, Hargrave KD, West M, Cullen E, Pal K, Behnke M, Kapadia SR, McNeil DW, Wu JC, Chow GC & Adams J (1992) Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. Journal of Medicinal Chemistry 35:1887-1897.
57. Klunder JM, Hoermann M, Cywin CL, David E, Brickwood JR, Schwartz R, Barringer KJ, Pauletti D, Shih C-K, Erickson DA, Sorge CL, Joseph DP, Hattox SE, Adams J & Grob PM (1998) Novel nonnucleoside inhibitor of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potenet broad-spectrum inhibitors of wild-type and mutant enzymes. Journal of Medicinal Chemistry 41:2960-2971.
58. Kroeger MB, Rouzer CA, Taneyhill LA, Smith NA, Hughes SH, Boyer PL, Janssen PAJ, Moereels H, Koymans L, Arnold E, Ding J, Das K, Zhang W, Michejda CJ & Smith RH Jr (1995) Molecular modelling studies of HIV-1 reverse transcriptase non-nucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Protein Science 4:2203-2222.
59. Kukla MJ, Breslin HJ, Pauwels R, Fedde CL, Miranda M, Scott MK, Sherrill RG, Raeymaekers A, Van Gelder J, Andries K, Janssen MAC, De Clercq E & Janssen PAJ (1991a) Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. Journal of Medicinal Chemistry 34:746-751.
60. Kukla M J, Breslin HJ, Diamond CJ, Grous PP, Ho CY, Miranda M, Rodgers JD, Sherrill RG, De Clercq E, Pauwels R, Andries K, Moens LJ, Janssen MAC & Janssen PAJ (1991b) Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 2. Journal of Medicinal Chemistry 34:3187-3197.
61. Larder BA, Purifoy DJM, Powell KL & Darby G (1987). Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature 327:716-717.
62. McMahon JB, Gulakowski RJ, Weislow OS, Shultz RJ, Narayanan VL, Clanton DJ, Pedemonte R, Wassmundt FW, Buckheit RW Jr, Decker WD, White EL, Bader JP & Boyd MR (1993) Diarylsulphones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 37:754-760.
63. Mai A, Artico M, Sbardella G, Massa S, Loi AG, Tramontano E, Scano P & La Colla P (1995) Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. Journal of Medicinal Chemistry 38:3258-3263.
64. Mai A, Artico M, Sbardella G, Quartarone S, Massa S, Loi AG, De Montis A, Scintu F, Putzolu M & La Colla P (1997) Dihydro(alkythio)(naphtylmethyl)oxopynmidmes: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. Journal of Medicinal Chemistry 40:1447-1454.
65. Mai A, Artico M, Sbardella G, Massa S, Novellino E, Greco G, Loi AG, Tramontano E, Marongiu ME & La Colla P (1999). 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)- ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. Journal of Medicinal Chemistry 42:619-627.
66. Mao C, Vig R, Venkatachalam TK, Sudbeck EA & Uckun FM (1998) Structure-based design of N-[2-(1-piperidinylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea as potent non-nudeoside inhibitors of HIV-1 reverse transcriptase. Bioorganic & Medicinal Chemistry Letters 8:2213-2218.
67. Massa S, Mai A, Artico M, Sbardella G, Tramontano E, Loi AG, Scano P & La Colla P (1995) Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1. Antiviral Chemistry & Chemotherapy 6:1-8.
68. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih C-K, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanes R, Eckner RJ, Koup RA & Sullivan JL (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
69. Mertens A, Zilch H, König B, Schäfer W, Poll T, Kampe W, Seidel H, Leiser U & Leinert H (1993) Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity. Journal of Medicinal Chemistry 36:2526-2536.
70. Miller V, de Bethune M-P, Kober A, Stürmer M, Hertogs K, Pauwels R, Stoffels P & Staszewski S (1998) Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrobial Agents and Chemotherapy 42:3123-3129.
71. Miyasaka T, Tanaka H, Baba M, Hayakawa H, Walker RT, Balzarini J & De Clercq E (1989) A novel lead for specific anti-HIV-1 agents: 1-[(2hydroxyethoxy)methyl]-6-(phenylthio)thymine. Journal of Medicinal Chemistry 32:2507-2509.
72. Neamati N, Mazumder A, Zhao H, Sunder S, Burke TR Jr, Schultz RJ & Pommier Y (1997) Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrobial Agents and Chemotherapy 41:385-393.
73. Nugent AR, Schlachter ST, Murphy MJ, Cleek GJ, Poel TJ, Wishka DG, Graber DR, Yagi Y, Keiser BJ, Olmsted RA, Kopta LA, Swaney SM, Poppe SM, Morris J, Tarpley WG & Thomas RC (1998) Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV. Journal of Medicinal Chemistry 41:3793-3803.
74. Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman JM, Emini EA & Goldman ME (1991) Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. Journal of Virology 65:4887-4892.
75. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen ACM, De Clercq E & Janssen PAJ (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474.
76. Pauwels R, Andries K, Debyser Z, Van Daele P, Schols D, Stoffels P, De Vreese K, Woestenborghs R, Vandamme A-M, Janssen CGM, Anne J, Cauwenbergh G, Desmyter J, Heykants J, Janssen MAC, De Clercq E & Janssen PAJ (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA 90:1711-1715.
77. Pauwels R, Andries K, Debyser Z, Kukla MJ, Schols D, Breslin HJ, Woestenborghs R, Desmyter J, Janssen MAC, De Clercq E & Janssen PAJ (1994) New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and thione derivates are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrobial Agents and Chemotherapy 38:2863-2870.
78. Pontikis R, Benhida R, Aubertin A-M, Grierson DS & Monneret C (1997) Synthesis and anti-HIV activity of novel N-1 side chain-modified analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). Journal of Medicinal Chemistry 40:1845-1854.
79. Proudfoot JR, Hargrave KD, Kapadia SR, Patel UR, Grozinger KG, McNeil DW, Cullen E, Cardozo M, Tong L, Kelly TA, Rose J, David E, Mauldin SC, Fuchs VU, Vitous J, Hoermann M, Klunder JM, Raghaven P, Skiles JW, Mui P, Richman DD, Sullivan JL, Shih C-K, Grob PM & Adams J (1995a) Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes. Journal of Medicinal Chemistry 38:4830-4838.
80. Proudfoot JR, Patel UR, Kapadia SR & Hargrave KD (1995b) Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 3. Dipyrido[2,3-b:2′,3′-e]diazepinones. Journal of Medicinal Chemistry 38:1406-1410.
81. Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D & Stuart D (1995) The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 3:915-926.
82. Romero DL, Busso M, Tan C-K, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L & Tarpley WG (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences, USA 88:8806-8810.
83. Romero DL, Morge RA, Biles C, Berrios-Pena N, May PD, Palmer JR, Johnson PD, Smith HW, Busso M, Tan C-K, Voorman RL, Reusser F, Althaus IW, Downey KM, So AG, Resnick L, Tarpley WG & Aristoff PA (1994) Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors. Journal of Medicinal Chemistry 37:999-1014.
84. Romero DL, Olmsted RA, Poel TJ, Morge RA, Biles C, Keiser BJ, Kopta LA, Friis JM, Hosley JD, Srefanski KJ, Wishka DG, Evans DB, Morris J, Stehle RG, Sharma SK, Yagi Y, Voorman RL, Adams WJ, Tarpley WG & Thomas RC (1996) Targeting delavirdine/atevirdine resistant: HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors. Journal of Medicinal Chemistry 39:3769-3789.
85. Roth T, Morningstar ML, Boyer PL, Hughes SH, Buckheit RW Jr & Michejda CJ (1997) Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles. Journal of Medicinal Chemistry 40:4199-4207.
86. Saari WS, Wai JS, Fisher TE, Thomas CM, Hoffman JM, Rooney CS, Smith AM, Jones JH, Bamberger DL, Goldman ME, O'Brien JA, Nunberg JH, Quintero JC, Schleif WA, Emini EA & Anderson PS (1992) Synthesis and evaluation of 2-pyridinone derivatives as specific HIV-1-reverse transcriptase inhibitors. 2. Analogs of 3-aminopyridin-2(1H)-one. Journal of Medicinal Chemistry 35:3792-3802.
87. Sahlberg C, Noreen R, Engelhardt P, Högberg M, Kangasmetsä J, Vrang L & Zhang H (1998) Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry Letters 8:1511-1516.
88. Silvestri R, Artico M, Massa S, Stefancich G, Congeddu E, Putzolu M & La Colla P (1997). Sulfone derivatives with anti-HIV activity. Il Farmaco 52:323-329.
89. Sudbeck EA, Mao C, Vig R, Venkatachalam TK, Tuel-Ahlgren L & Uckun FM (1998) Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrobial Agents and Chemotherapy 42: 3225-3233.
90. Tanaka H, Baba M, Saito S, Miyasaka T, Takashima H, Sekiya K, Ubasawa M, Nitta I, Walker RT, Nakashima H & De Clercq E (1991) Specific anti-HIV-1 'acyclonucleosides' which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. Journal of Medicinal Chemistry 34:1508-1511.
91. Tanaka H, Takashima H, Ubasawa M, Sekiya K, Nitta I, Baba M, Shigeta S, Walker RT, De Clercq E & Miyasaka T (1992a) Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. Journal of Medicinal Chemistry 35:337-345.
92. Tanaka H, Takashima H, Ubasawa H, Sekiya K, Nitta I, Baba M, Shigeta S, Walker RT, De Clercq E & Miyasaka T (1992b) Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. Journal of Medicinal Chemistry 35:4713-4719.
93. Tanaka H, Takashima H, Ubasawa M, Sekiya K, Inouye N, Baba M, Shigeta S, Walker RT, De Clercq E & Miyasaka T (1995) Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. Journal of Medicinal Chemistry 38:2860-2865.
94. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PAJ & Arnold E (1994) Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Journal of Molecular Biology 243:369-387.
95. Tucker TJ, Lumma WC & Culberson JC (1996) Development of nonnucleoside HIV reverse transcriptase inhibitors. Methods in Enzymology 275:440-472.
96. Velazquez S, Alvarez R, Perez C, Gago F, De Clercq E, Balzarini J & Camarasa M-J (1998) Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkyl carbamoyl 1,2,3-triazole-TSAO analogues. Antiviral Chemistry & Chemotherapy 9:481-489.
97. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA & Uckun FM (1998) Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase. Bioorganic & Medicinal Chemistry 6:1789-1797.
98. Wai JS, Williams TM, Bamberger DL, Fisher TE, Hoffman JM, Hudcosky RJ, MacTough SC, Rooney CS, Saari WS, Thomas CM, Goldman ME, O'Brien JA, Emini EA, Nunberg JH, Quintero JC, Schleif WA & Anderson PS (1993) Synthesis and evaluation of 2-pyridinone derivatives as specific HIV-1 reverse transcriptase Inhibitors. 3. Pyridyl and phenyl analogs of 3-aminopyridin-2(1H)-one. Journal of Medicinal Chemistry 36:249-255.
99. Williams TM, Ciccarone TM, MacTough SC, Rooney CS, Balani SK, Condra JH, Emini EA, Goldman ME, Greenlee WJ, Kauffman LR, O'Brien JA, Sardana VV, Schleif WA, Theoharides AD & Anderson PS (1993) 5-Chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. Journal of Medicinal Chemistry 36:1291-1294.
100. Wishka DG, Graber DR, Kopta LA, Olmsted RA, Friis JM, Hosley JD, Adams WJ, Seest EP, Castle TM, Dolak LA, Keiser BJ, Yagi Y, Jeganathan A, Schlachter ST, Murphy MJ, Cleek GJ, Nugent RA, Poppe SM, Swaney SM, Han F, Watt W, White WL, Poel T-J, Thomas RC, Voorman RL, Stefanski KJ, Stehle RG, Tarpley WG & Morris J (1998a) (-)-6-Chloro-2-[(1-furo[2,3-c]pyridin-5-yl-ethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor. Journal of Medicinal Chemistry 41:1357-1360.
101. Wishka DG, Graber DR, Seest EP, Dolak AD, Han F, Watt W & Morris J (1998b) Stereoselective synthesis of furo[2,3-c]pyridine pyrimidine thioethers, a new class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Journal of Organic Chemistry 63:7851-7859.
102. Witvrouw M, Arranz ME, Pannecouque C, Declerq R, Jonckheere H, Schmit J-C, Vandamme A-M, Diaz JA, Ingate ST, Desmyter J, Esnouf R, Van Meervelt L, Vega S, Balzarini J & De Clercq E (1998) 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. Antimicrobial Agents and Chemotherapy 42:618-623.
103. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, Pettibone DJ, O'Brien JA, Ball RG, Balani SK, Lin JH, Chen I-W, Schleif WA, Sardana VV, Long WJ, Byrnes VW & Emini EA (1995a) L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 39:2602-2605.
104. Young SD, Britcher SF, Payne LS, Tran LO & Lumma WC (1995b) WO95/20389.
105. Zembower DE, Liao S, Flavin MT, Xu Z-Q, Stup TL, Buckheit RW Jr, Khilevich A, Mar AA & Sheinkman AK (1997) Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C). Journal of Medicinal Chemistry 40:1005-1017.